Cartesian Therapeutics Inc.

06/16/2025 | Press release | Distributed by Public on 06/16/2025 05:06

Proxy Results (Form 8-K)

Item 5.07 Submission of Matters to a Vote of Security Holders.
On June 13, 2025, Cartesian Therapeutics, Inc. (the "Company") held the 2025 Annual Meeting of Stockholders (the "Annual Meeting"). A total of 21,868,804 shares of the Company's common stock, par value $0.0001 per share (the "common stock"), were present electronically or represented by proxy at the meeting, representing approximately 84.31% of the Company's outstanding common stock as of the April 14, 2025 record date. The following are the voting results for the proposals considered and voted upon at the meeting, all of which were described in the Proxy Statement.
Proposal 1 - Election of three Class III Directors to serve until the 2028 Annual Meeting of Stockholders, and until their respective successors have been duly elected and qualified.
NOMINEE
Votes FOR
Votes WITHHELD
Broker Non-Votes
Timothy C. Barabe, M.B.A.
19,208,637 651,344 2,008,823
Carsten Brunn, Ph.D.
19,841,557 18,424 2,008,823
Nishan de Silva, M.D., M.B.A.
19,840,306 19,675 2,008,823
Based on the votes set forth above, each director nominee was duly elected to serve until the Company's 2028 Annual Meeting of Stockholders, and until their respective successors have been duly elected and qualified.
Proposal 2 - Approval, on a non-binding and advisory basis, of a resolution approving the compensation of the Company's named executive officers.
Votes FOR
Votes AGAINST
Votes ABSTAINED
Broker Non-Votes
19,701,123 157,132 1,726 2,008,823
Based on the votes set forth above, the stockholders approved, on a non-binding and advisory basis, a resolution approving the compensation of our named executive officers.
Proposal 3 - Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2025.
Votes FOR
Votes AGAINST
Votes ABSTAINED
Broker Non-Votes
21,830,780 5,946 32,078 -
Based on the votes set forth above, the stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2025.
Cartesian Therapeutics Inc. published this content on June 16, 2025, and is solely responsible for the information contained herein. Distributed via SEC EDGAR on June 16, 2025 at 11:06 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at support@pubt.io